Ampa Ltd.
TTASE:AMPA1,480.00
ILA
+43.00
(+2.99%)
ISIN
IL0012252008
Return %
Stock
S&P 500
1Y
11.70
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
ILS
•
in mil. unless spec.Working Capital
ILS
•
in mil. unless spec.Growth Rates
ILS
•
in mil. unless spec.Quarterly Revenue
ILS
•
in mil. unless spec.Quarterly Earnings Per Share
ILS
•
in mil. unless spec.Quarterly Dividends Per Share
ILS
•
in mil. unless spec.Company Description
- CEO
- Zohar Levi
- Full Time Employees
- 295
- Sector
- Finance
- Industry
- Real estate development
- Address
- Ampa House Herzliya Pituach TA Israel 4685205
- IPO Date
- Jul 14, 2025
- Website
- ampa.co.il
- Similar Companies
- Business
- Ampa Ltd is a publicly traded Israeli technology and consumer health company specializing in non-invasive neuromodulation and related medical devices. Headquartered in Israel, it is focused on developing and commercializing brain stimulation platforms and associated therapeutic systems, with revenue generation tied to clinical adoption and device sales across regulatory-approved markets. Main products and services Ampa develops and markets FDA-cleared and CE-marked brain stimulation solutions, including portable and wearable neuromodulation devices; adjunct hardware and accessories; software platforms for stimulation protocols, patient monitoring, and data analytics; clinician training and support services; and related post-market surveillance and regulatory compliance packages. The company also offers research-use and commercial deployment platforms for neurotherapeutics, enabling remote monitoring, dose customization, and treatment optimization; service offerings include clinical consultation, study design assistance, and data-backed outcome reporting. Ampa’s product families span portable neurostimulation devices, integrated care bundles for outpatient and hospital settings, clinician dashboards, and patient-facing mobile interfaces designed to support home-based therapy. Additional revenue streams are derived from distribution partnerships, clinical trial collaborations, and licensing arrangements for technology cores and algorithms. Latest major company changes Ampa completes a nationwide rollout following FDA clearance of its Ampa One system, expanding access to non-invasive brain stimulation and increasing institutional adoption; secures an oversubscribed funding round led by specialized neurotech investors, elevating total fundraising to a multi-year high and fueling commercialization and scale-up; forms strategic partnerships with healthcare providers and research networks to bolster clinical evidence generation and market penetration; announces enhancements to its platform including improved portability, expanded indication coverage, and new software modules for remote monitoring and outcome tracking; and advances regulatory submissions and approvals to broaden geographic reach and product applicability. Additional context Industry and business segments: medical devices, digital health, neurostimulation, and pharmaceutical-adjacent R&D collaborations. Target markets and customers include hospitals, clinics, outpatient centers, research institutions, and medical professionals specializing in neurology, psychiatry, and rehabilitation. Geographic operations span Israel and North American markets with ongoing expansion into additional regulatory jurisdictions. Founding year and headquarters: founded in the early 2020s; headquartered in Israel. Subsidiaries and parent relationships: operates as Ampa Ltd with potential regional affiliates and distributors; engages in licensing and collaboration agreements with outside technology firms for device cores, software, and analytics capabilities.